Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026)
Exelixis (EXEL) posted quarterly Depreciation & Amortization (CF) of $6.9 million for Q2 2026, down 5.41% year-over-year from $7.3 million in Q2 2025, and little changed quarter-over-quarter from $6.9 million in Q1 2026.
Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Exelixis' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $6.9 million for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) fell 5.41% year-over-year to $6.9 million; the TTM figure through Apr 2026 stood at $28.7 million (down 3.74% YoY), while the FY2026 annual figure was $29.1 million, up 0.87% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $6.9 million, roughly flat from $6.9 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $7.6 million in Q1 2025, with the low at $4.5 million in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $6.9 million (2023), against an average of $6.6 million.
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 207.92% in 2022, then dropped 9.11% in 2026.
- Exelixis' Depreciation & Amortization (CF) stood at $5.9 million in 2022, then grew by 9.75% to $6.5 million in 2023, then gained by 14.22% to $7.5 million in 2024, then fell by 0.43% to $7.4 million in 2025, then declined by 6.39% to $6.9 million in 2026.
- Business Quant data shows EXEL's Depreciation & Amortization (CF) at $6.9 million in Q2 2026, $6.9 million in Q1 2026, and $7.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 6.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 6.98 Mn |
| Jul 3, 2026 | 6.98 Mn |
| Apr 3, 2026 | 6.95 Mn |
| Apr 3, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Mar 29, 2024 | 6.38 Mn |
| Mar 29, 2024 | 6.38 Mn |